A Clinical Comparison of Two Multifocal Toric Soft Contact Lenses

NCT06438601 — Not applicable, Completed, 36 participants, CooperVision, Inc.

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT06438601
StatusCompleted
PhaseNot applicable
Study typeInterventional; non randomized, crossover, masking: single, treatment
Enrollment36 (Actual)
SponsorCooperVision, Inc. (Industry)
ConditionsAstigmatism, Presbyopia
InterventionsLens A (omafilcon A), Lens B (comfilcon A) (Device)
Datesstart 2024-04-24, primary completion 2024-08-15, completion 2024-08-15, first posted 2024-06-03, last updated 2025-08-11
Locations1 site in United Kingdom

Related Papers Related Patents Related Grants Related Experts
All trials for Astigmatism All trials for Presbyopia All trials of Lens A (omafilcon A) All trials of Lens B (comfilcon A)

-Summary

This study aims to compare the short-term clinical performance of the two study contact lenses.

Expand all sections  ·  Collapse all

+Detailed description

The aim of this study is to evaluate the short-term clinical performance of two multifocal toric soft contact lenses after 15 minutes of daily wear each.

+Arms and interventions

ArmTypeInterventionsDescription
Lens A (omafilcon A)ExperimentalDevice: Lens A (omafilcon A)All participants will wear lens A for 15 minutes (Period 1).
Lens B (comfilcon A)ExperimentalDevice: Lens B (comfilcon A)All participants will wear lens B for 15 minutes (Period 2).
  • Lens A (omafilcon A) (Device): 15 minutes of daily wear.
  • Lens B (comfilcon A) (Device): 15 minutes of daily wear.

+Outcome measures

Primary outcomes

  • Subjective Distance Vision [At the end of 15 minutes of daily wear]: Subjective Distance Vision will be measured on a scale from 0-100 (Where 0= Extremely poor. Intolerable. Lenses cannot be worn. 100= Excellent. Unaware of any visual loss).

+Eligibility

Sex: All, ages: 35 Years to any

Inclusion Criteria:

1. They are aged 35 years or over and have capacity to volunteer.
2. They understand their rights as a subject and are willing to sign a Statement of Informed Consent.
3. They are willing and able to follow the protocol.
4. They agree not to participate in other clinical research for the duration of this study.
5. They are currently wearing soft contact lenses or have done so within the past 12 months.
6. They have a spherical prescription between +10.00 and -10.00DS inclusive, (based on the ocular refraction).
7. They have astigmatism of between -0.75 and -5.75DC (based on the ocular refraction) in each eye.
8. They have a reading addition component to their spectacle refraction of between +0.75 and +2.50DS.
9. They can be satisfactorily fitted with the study lenses.
10. They own a wearable pair of spectacles.

Exclusion Criteria:

1. They have an ocular disorder which would normally contraindicate contact lens wear.
2. They have a systemic disorder which would normally contra-indicate contact lens wear.
3. They are using any topical medications such as eye drops or ointment.
4. They have had cataract surgery.
5. They have had corneal refractive surgery.
6. They have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus.
7. They have any ocular abnormality which would, in the opinion of the investigator, normally contraindicate contact lens wear.
8. They have eye or health conditions including immunosuppressive or infectious diseases which would, in the opinion of the investigator, contraindicate contact lens wear or pose a risk to study personnel; or a history of anaphylaxis or severe allergic reaction.
9. They have taken part in any other contact lens or care solution clinical trial or research, within two weeks prior to starting this study.

+Posted results

Participant flow

MilestoneLens A (Omafilcon A)Lens B (Comfilcon A)
Started360
Completed340
Not completed20

Outcome results

  • Subjective Distance Vision (Primary), Mean, units on a scale: Lens A (Omafilcon A) 77.1 +/- 19.6; Lens B (Comfilcon A) 80.0 +/- 14.5

Adverse events

Time frame: Through study completion, approximately sixteen weeks.

ArmDeathsSerious adverse eventsOther adverse events
Lens A (Omafilcon A)0/36 (0.0%)0/36 (0.0%)0/36 (0.0%)
Lens B (Comfilcon A)0/34 (0.0%)0/34 (0.0%)0/34 (0.0%)
No Intervention0/36 (0.0%)0/36 (0.0%)2/36 (5.6%)

Other adverse events by term

TermOrgan systemLens A (Omafilcon A)Lens B (Comfilcon A)No Intervention
Suspect vitreous detachmentEye disorders0/360/341/36
Sub-conjunctival haemorrhageEye disorders0/360/341/36

+Locations (1)

FacilityCityCountryStatus
The University of ManchesterManchesterUnited Kingdom

+Study documents

+Investigators